What is EVAX's P/E ratio?

Evaxion Biotech AS (EVAX) currently trades at a P/E ratio of 5.09.

Evaxion Biotech AS reports a Return on Equity (ROE) of -73.90%.

What is EVAX's dividend yield?

Evaxion Biotech AS offers a dividend yield of 0.00%.

What is EVAX's Quality Score?

Our AI rates EVAX's overall financial quality at 23 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy EVAX?

Our AI Timing Score for EVAX is 0 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does EVAX belong to?

Evaxion Biotech AS is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange

Evaxion Biotech AS (EVAX) Stock Price

Stock Check Daily update data at 8:30 AM
(Price: 2026-08-03 | FS: 2026-03-31)

EVAX AI Analysis Summary

Our AI summary for EVAX: Evaxion Biotech AS (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 5.09, ROE of -73.90%, a dividend yield of 0.00%. Its financial Quality Score stands at 23/100 — fundamentals below the market average. The AI Timing Score is 0/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

EVAX

Evaxion Biotech AS

US:NASDAQ STOCK Healthcare >> Biotechnology News 74

USD 2.79

-0.03 (-1.06%) Day Change

Watchlist Portfolio Compare Chart

5.09

P/E

0.79

D/E

-73.9%

ROE

-41.3%

ROA

0.00%

Div Yield

-0.09

PEG

EVAXION BIOTECH AS
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 2.79 Price -0.03 (-1.06%) Day Change	NEWS SCORE: 74

EVAX, the overall quality is not good ( Quality = 23) and the timing to buy is ...(Sign In to See)...

Loading chart...

23 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Negative growth of ROE in the last year.
ROE is decreasing significantly
Acceleration of ROA growth rate is below our criteria.
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...

Quality Factors

45%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	74
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	2.79
PBV / Sector	1.78 / 44,219.29
Earning Per Share	-1.16

PE / Sector	5.09 / 19.28 GREAT
PEG or PE/Growth / Sector	-0.09 / 1.23
Average 1M Daily Value	0.04 M GREAT
Average 1W Daily Value	0.04 M GREAT

Timing Factors

57%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

41%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

47%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	-129.25 / 98.22
NPM Average (%) / Sector	-7,713.96 / -1,697.63
NPM Change Average (%) / Sector	N/A / 5,097.97
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-41.28 / 185,260.96
ROA Average (%) / Sector	-85.98 / 36,684.70
ROA Change Average (%) / Sector	-0.82 / 422,221.66
ROE (%) / Sector	-73.90 / 243,762.23
ROE Average (%) / Sector	141.87 / 48,758.47 GREAT
ROE Change Average (%) / Sector	-68.66 / 424,968.10
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -0.19

Registration Details

Analyze Date	2026-08-04 08:01:29
Symbol	EVAX
Name	EVAXION BIOTECH AS
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	8.34 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	23.52 / 9,645.64

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: Dr. Neergaards Vej, Horsholm, Denmark, 2970

Phone: 45 53 53 18 50

Website: https://evaxion.ai

Sector: Healthcare >> Biotechnology

Description: Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of advanced melanoma; EVX-03, DNA-based cancer vaccine for the treatment of solid tumors; and EVX-04, a therapeutic cancer vaccine candidate, which is in phase 1 trial for acute myeloid leukemia. Its programs also include vaccines that are in pre-clinical stage, which includes EVX-B1, a multi-component prophylactic vaccine targeting skin and soft tissue infections with S. aureus bacteria; EVX-B2 to target multi-component prophylactic vaccine against gonorrhea bacteria; EVX-B3 to target bacterial pathogen associated with repeated infections; and EVX-V1, a multi-component prophylactic vaccine candidate for cytomegalovirus. The company was formerly known as Evaxion Biotech A/S and changed its name to Evaxion A/S in May 2025. Evaxion A/S was incorporated in 2008 and is based in Horsholm, Denmark.